The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety, pharmacokinetics, and antitumor activity of MEDI3617, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Ronald B. Natale
Research Funding - MedImmune
Naiyer A. Rizvi
Research Funding - MedImmune
Jeffrey R. Infante
No relevant relationships to disclose
Lindsay J. Joseph
No relevant relationships to disclose
Jaye Viner
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Jennifer T. McDevitt
Employment or Leadership Position - MedImmune
Fei Ji
Employment or Leadership Position - MedImmune
Soyoung Shin
Employment or Leadership Position - MedImmune
Meina Liang
Employment or Leadership Position - MedImmune
Stock Ownership - AstraZeneca
Howard A. Burris
Research Funding - MedImmune